Whole-genome sequencing has brought the cancer genomics community into new territory.
Thanks to the sheer power provided by the thousands of mutations present in each patient's …

Intra-tumor heterogeneity (ITH) is a mechanism of therapeutic resistance and therefore an
important clinical challenge. However, the extent, origin, and drivers of ITH across cancer …

Neuroendocrine neoplasms (NENs) comprise well-differentiated neuroendocrine tumors
(NETs) and poorly differentiated neuroendocrine carcinomas (NECs). Treatment options for …

Mutations are the driving force of evolution, yet they underlie many diseases, in particular,
cancer. They are thought to arise from a combination of stochastic errors in DNA processing …

Different mutational processes leave characteristic patterns of somatic mutations in the
genome that can be identified as mutational signatures. Determining the contributions of …

Both TP53 and ESR1 mutations occur frequently in estrogen receptor positive (ER+)
metastatic breast cancers (MBC) and their distinct roles in breast cancer tumorigenesis and …

Neuroblastoma is a pediatric solid tumor characterized by strong clinical heterogeneity.
Although clinical risk-defining genomic alterations exist in neuroblastomas, the mutational …

As a cancer develops, its cells accrue new mutations, resulting in a heterogeneous, complex
genomic profile. We make use of this heterogeneity to derive simple, analytic estimates of …

The cancer cell fraction (CCF), or proportion of cancerous cells in a tumor containing a
single-nucleotide variant (SNV), is a fundamental statistic used to quantify tumor …

The evolutionary history of hepatobiliary cancers is embedded in their genomes. By
analysing their catalogue of somatic mutations and the DNA sequence context in which they …